KIR ligand mismatched allogeneic cord blood transplantation for the advanced neuroblastoma

KIR ligand mismatched allogeneic cord blood transplantation for the advanced neuroblastoma - KIR ligand mismatched allogeneic cord blood transplantation for the advanced neuroblastoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015165

Enrollment

Registered

2014-09-15

Start date

2012-06-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Interventions

KIR ligand mismatched cord blood transplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: advanced neuroblastoma 1) refractory for chemotherapy 2) N-MYC amplification (more than 10 copies) 3) more than 10 years 4) relapse

Exclusion criteria

Exclusion criteria: 1 uncontroled infection 2 allergy

Design outcomes

Primary

Measure	Time frame
3 years event free survival after the transplantation	—

Countries

Japan

Contacts

Public ContactYoshiyuki Takahashi

Nagoya University Graduate School of Medicine Department of Pediatrics

ytakaha@med.nagoya-u.ac.jp052-744-2294

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026